Adrenergic alpha-1 Receptor Antagonists
"Adrenergic alpha-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
| Descriptor ID |
D058668
|
| MeSH Number(s) |
D27.505.519.625.050.200.100.100 D27.505.696.577.050.200.100.100
|
| Concept/Terms |
Adrenergic alpha-1 Receptor Antagonists- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha 1 Receptor Antagonists
- Adrenergic alpha1-Antagonists
- Adrenergic alpha1 Antagonists
- alpha1-Antagonists, Adrenergic
- alpha-1 Adrenergic Blocking Agents
- alpha 1 Adrenergic Blocking Agents
- alpha1-Adrenoceptor Blocker
- alpha1 Adrenoceptor Blocker
- Adrenergic alpha-1 Antagonists
- Adrenergic alpha 1 Antagonists
- alpha-1 Antagonists, Adrenergic
- Adrenergic alpha-1 Receptor Blockers
- Adrenergic alpha 1 Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-1 Receptor Antagonists".
This graph shows the total number of publications written about "Adrenergic alpha-1 Receptor Antagonists" by people in this website by year, and whether "Adrenergic alpha-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-1 Receptor Antagonists" by people in Profiles.
-
Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant. Am J Drug Alcohol Abuse. 2020; 46(2):184-193.
-
Are There Effective Psychopharmacologic Treatments for PTSD? J Clin Psychiatry. 2018 12 18; 80(3).
-
Smashing the strict hierarchy: three cases of clinical decision support malfunctions involving carvedilol. J Am Med Inform Assoc. 2018 11 01; 25(11):1552-1555.
-
Pharmacogenetics of Dopamine ?-Hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol. 2019 05; 24(3):531-538.
-
Adrenergic receptor agonists induce the differentiation of pluripotent stem cell-derived hepatoblasts into hepatocyte-like cells. Sci Rep. 2017 12 01; 7(1):16734.
-
In vivo metabolic investigation of silodosin using UHPLC-QTOF-MS/MS and in silico toxicological screening of its metabolites. J Mass Spectrom. 2016 Oct; 51(10):867-882.
-
Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men. Urology. 2016 05; 91:150-3.
-
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens. 2016 09; 30(9):549-54.
-
Dacryocystitis and Failure of Dacryocystorhinostomy Associated with Tamsulosin. Ophthalmic Plast Reconstr Surg. 2015 Nov-Dec; 31(6):492.
-
Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial). Health Technol Assess. 2015 Aug; 19(63):vii-viii, 1-171.